Skip to main content

Table 1 Comparison of the baseline epidemiological characteristics of the different groups

From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Characteristics

Group

P value

Total

1-CRZ

1-PP

N1-PP

Total, n

73

32

28

13

 

Gender, n (%)

 Male

36 (49.3)

19 (59.4)

11 (39.3)

6 (46.2)

0.290

 Female

37 (50.7)

13 (40.6)

17 (60.7)

7 (53.8)

 

Median age, year (range)

51.4 (23–73)

53.3 (30–73)

49.6 (23–71)

43.2 (23–61)

0.045

Smoking, n (%)

Never

49 (67.1)

19(59.4)

21 (75.0)

9 (69.2)

0.431

Current/Former

24 (32.9)

13 (40.6)

7 (25.0)

4 (30.8)

 

ECOG score, n (%)

0 or 1

69 (94.5)

30 (93.8)

26 (92.9)

13 (100.0)

0.625

> = 2

4 (5.5)

2 (6.2)

2 (7.1)

0 (0)

 

Extent of disease, n (%)

Locally advanced

14 (19.2)

6 (18.8)

5 (17.9)

3 (23.1)

0.922

Metastatic

59 (80.8)

26 (81.2)

23 (82.1)

10 (76.9)

 
  1. Note. — Unless otherwise indicated, the data are shown as numbers with percentages in parentheses. The statistical analysis for age was performed using the Mann–Whitney test. The statistical analyses for other clinical features were performed using the Chi-Square test